CD274 and osteosarcoma: Similarly, CRISPR/Cas9 knockout of PD-L1 enhanced the sensitivity of human osteosarcoma cells to doxorubicin and paclitaxel and blocked the ability to form three-dimensional spheroids in vitro [49].